QT time prolongation
Adverse drug events
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Explanations of the substances for patients
We have no additional warnings for the combination of abarelix and mianserin. Please also consult the relevant specialist information.
The reported changes in exposure correspond to the changes in the plasma concentration-time curve [ AUC ]. We do not expect any change in exposure for abarelix, when combined with mianserin (100%). We do not expect any change in exposure for mianserin, when combined with abarelix (100%).
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of abarelix is unknown. The terminal half-life [ t12 ] is rather long at 316.8 hours and constant plasma levels [ Css ] are only reached after more than 1267.2 hours. The protein binding [ Pb ] is 97.5% strong. The metabolism via cytochromes is currently still being worked on.
Mianserin has a low oral bioavailability [ F ] of 25%, which is why the maximum plasma level [Cmax] tends to change strongly with an interaction. The terminal half-life [ t12 ] is rather long at 41 hours and constant plasma levels [ Css ] are only reached after more than 164 hours. The protein binding [ Pb ] is moderately strong at 95%. The metabolism takes place via CYP1A2, CYP2D6 and CYP3A4, among others.
|Serotonergic Effects a||0||Ø||Ø|
Rating: According to our knowledge, neither abarelix nor mianserin increase serotonergic activity.
|Kiesel & Durán b||1||Ø||+|
Recommendation: As a precaution, attention should be paid to anticholinergic symptoms, especially after increasing the dose and at doses in the upper therapeutic range.
Rating: Mianserin only has a mild effect on the anticholinergic system. The risk of anticholinergic syndrome with this medication is rather low if the dosage is in the usual range. According to our knowledge, abarelix does not increase anticholinergic activity.
QT time prolongation
Rating: In combination, abarelix and mianserin can potentially trigger ventricular arrhythmias of the torsades de pointes type.
General adverse effects
|Side effects||∑ frequency||aba||mia|
|Aplastic anemia||0.0 %||n.a.||0.01|
Based on your answers and scientific information, we assess the individual risk of undesirable side effects. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.
Abstract: The kinetics of mianserin have been evaluated in eight healthy male volunteers following a single oral dose of 60 mg. Plasma and blood concentrations of mianserin were measured by gas chromatography-mass fragmentography. The peak blood concentration observed was 65 microgram/1 at 3 h following the dose. Mean kinetic parameters (and range) calculated from the blood concentrations were: (t1/2)abs 1.1 h (0.3-2.8), (t1/2) alpha 2.5 h (0.9-4.7), (t1/2) beta 21 h (14-33), (Vd) beta 27.5 l/kg (16.8-46.5) and Cloral 0.98 l/kg/h (0.47-1.75). Blood/plasma concentration ratios ranged from 0.50-0.74.
Abstract: No Abstract available